RESPONSE RATES IN THE PHASE 3 CLARINET TRIAL OF LANREOTIDE DEPOT VS PLACEBO IN PATIENTS WITH METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS).

被引：0
|
作者：
Iwasaki, Michiko [1 ]
Wolin, Edward [2 ]
Dasari, Arvind [1 ]
Liyanage, Nilani [3 ]
Lowenthal, Susan Pitman [4 ]
Phan, Alexandria [5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
[3] Ipsen Biopharmaceut Inc, Boulogne, France
[4] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
[5] Houston Methodist Hosp, GI Med Oncol, Houston, TX USA
来源：
ONCOLOGY NURSING FORUM | 2016年 / 43卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
207
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [1] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
  • [2] Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Phan, Alexandria T.
    Dasari, Arvind
    Liyanage, Nilani
    Cox, David
    Lowenthal, Susan Pitman
    Wolin, Edward M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [3] Lanreotide vs. Octreotide-LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis
    Ryan, Pamela
    McBride, Ali
    Ray, David
    Pulgar, Sonia
    Ramirez, Robert
    Elquza, Emad
    Favaro, Justin
    Dranitsaris, George
    [J]. PANCREAS, 2019, 48 (03) : 450 - 450
  • [4] The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Saif, Wasif M.
    Parikh, Rohan
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh P.
    Soares, Heloisa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] The Sequencing of Lanreotide (LAN) After Octreotide LAR (OCT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Saif, Wasif M.
    Parikh, Rohan C.
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Halfdanarson, Thorvardur R.
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh
    Soares, Heloisa
    [J]. PANCREAS, 2019, 48 (03) : 450 - 450
  • [6] Differential prognosis according to metastatic patterns in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Rosas, V.
    Rosales Sotomayor, A.
    Hernandez Martinez, A.
    Gamboa Dominguez, A.
    Noguez Ramos, A.
    Huitzil Melendez, F. D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S416 - S417
  • [7] The CLARINET Study - Assessing the Effect of Lanreotide Autogel on Tumor Progression-Free Survival in Patients with Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Joelle, Blumberg
    Nilani, Liyanage
    Martyn, Caplin
    [J]. PANCREAS, 2012, 41 (02) : 343 - 343
  • [8] Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Inbal Uri
    Simona Grozinsky-Glasberg
    [J]. Clinical Diabetes and Endocrinology, 4 (1):
  • [9] Phase II Study of Sunitinib Following Hepatic Artery Embolization for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Strosberg, Jonathan
    Campos, Tiffany
    Kvols, Larry
    [J]. PANCREAS, 2010, 39 (02) : 280 - 281
  • [10] ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Gomez-Panzani, E.
    Vinik, A.
    Wolin, E.
    Audry, H.
    [J]. NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 271 - 271
12345